{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:02:38Z","timestamp":1753891358886,"version":"3.41.2"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Human immunodeficiency virus (HIV) induced AIDS causes a large number of infections and deaths worldwide every year, still no vaccines are available to prevent infection. Recombinant herpes simplex virus type 1 (HSV-1) vector-based vaccines coding the target proteins of other pathogens have been widely used for disease control. Here, a recombinant virus with HIV-1 <jats:italic>gp160<\/jats:italic> gene integration into the internal reverse (IR) region-deleted HSV-1 vector (HSV-BAC), was obtained by bacterial artificial chromosome (BAC) technology, and its immunogenicity investigated in BALB\/c mice. The result showed similar replication ability of the HSV-BAC-based recombinant virus and wild type. Furthermore, humoral and cellular immune response showed superiority of intraperitoneal (IP) administration, compared to intranasally (IN), subcutaneous (SC) and intramuscularly (IM), that evidenced by production of significant antibody and T cell responses. More importantly, in a prime-boost combination study murine model, the recombinant viruses prime followed by HIV-1 VLP boost induced stronger and broader immune responses than single virus or protein vaccination in a similar vaccination regimen. Antibody production was sufficient with huge potential for viral clearance, along with efficient T-cell activation, which were evaluated by the enzyme-linked immunosorbent assay (ELISA) and flow cytometry (FC). Overall, these findings expose the value of combining different vaccine vectors and modalities to improve immunogenicity and breadth against different HIV-1 antigens.<\/jats:p>","DOI":"10.3389\/fmicb.2023.1136664","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T04:23:02Z","timestamp":1679026982000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB\/c mice"],"prefix":"10.3389","volume":"14","author":[{"given":"Beibei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenghai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1128\/jvi.75.13.6183-6192.2001","article-title":"Varicella-zoster virus infection of human dendritic cells and transmission to T cells: implications for virus dissemination in the host","volume":"75","author":"Abendroth","year":"2001","journal-title":"J. Virol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"101495","DOI":"10.1016\/j.trim.2021.101495","article-title":"T helper type (Th1\/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: from cytokines produced to immune responses","volume":"70","author":"Aleebrahim-Dehkordi","year":"2022","journal-title":"Transpl. Immunol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/ni.3157","article-title":"Innate immunity against HIV-1 infection","volume":"16","author":"Altfeld","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12865-018-0278-4","article-title":"Prevalence and associated factors of treatment failure among HIV\/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia","volume":"19","author":"Ayele","year":"2018","journal-title":"BMC Immunol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/nrmicro3132","article-title":"Past, present and future: 30 years of HIV research","volume":"11","author":"Barre-Sinoussi","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e00616-18","DOI":"10.1128\/JVI.00616-18","article-title":"Immunization by replication-competent controlled herpesvirus vectors","volume":"92","author":"Bloom","year":"2018","journal-title":"J. Virol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1006\/viro.1999.9653","article-title":"Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more \u03b1-genes: ICP4, ICP27, ICP22, and ICP0","volume":"256","author":"Brehm","year":"1999","journal-title":"Virology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1128\/jvi.76.8.3678-3687.2002","article-title":"Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity","volume":"76","author":"Brockman","year":"2002","journal-title":"J. Virol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1517\/14712598.2015.1021328","article-title":"Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine","volume":"15","author":"Cafaro","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1097\/00002030-200317004-00009","article-title":"Present status of human HIV vaccine development","volume":"17","author":"Calarota","year":"2003","journal-title":"AIDS"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41591-020-0774-y","article-title":"Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption","volume":"26","author":"Colby","year":"2020","journal-title":"Nat. Med."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0140-6736(91)91636-9","article-title":"Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein","volume":"337","author":"Cooney","year":"1991","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/10439","article-title":"Strategies used by human immunodeficiency virus that allow persistent viral replication","volume":"5","author":"Desrosiers","year":"1999","journal-title":"Nat. Med."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nm0304-221","article-title":"Prospects for an AIDS vaccine","volume":"10","author":"Desrosiers","year":"2004","journal-title":"Nat. Med."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e16563","DOI":"10.1371\/journal.pone.0016563","article-title":"Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus","volume":"6","author":"Ding","year":"2011","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"7410","DOI":"10.1016\/j.vaccine.2007.08.015","article-title":"HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime","volume":"25","author":"Duke","year":"2007","journal-title":"Vaccine"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1089\/aid.2004.20.989","article-title":"Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV gag proteins: comparison of intranasal and intramuscular vaccination routes","volume":"20","author":"Egan","year":"2004","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1126\/science.1100368","article-title":"Developing an AIDS vaccine: need, uncertainty, hope","volume":"304","author":"Emini","year":"2004","journal-title":"Science."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/14760584.2019.1640117","article-title":"Novel prime-boost vaccine strategies against HIV-1","volume":"18","author":"Excler","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/hum.2010.020","article-title":"Phase I\/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver","volume":"21","author":"Geevarghese","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/14712598.2016.1193594","article-title":"HIV-1 immunogen: an overview of almost 30 years of clinical testing of a candidate therapeutic vaccine","volume":"16","author":"Graziani","year":"2016","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1128\/jvi.76.15.7506-7517.2002","article-title":"Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins","volume":"76","author":"Haglund","year":"2002","journal-title":"J. Virol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1128\/jvi.76.11.5565-5580.2002","article-title":"Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses","volume":"76","author":"Hocknell","year":"2002","journal-title":"J. Virol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.4161\/hv.28659","article-title":"The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination","volume":"10","author":"Hollister","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/s0076-6879(99)06022-x","article-title":"Genetic manipulation of herpes simplex virus using bacterial artificial chromosomes","volume":"306","author":"Horsburgh","year":"1999","journal-title":"Methods Enzymol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.vaccine.2013.12.022","article-title":"Effects of different promoters on the virulence and immunogenicity of a HIV-1 Env-expressing recombinant vaccinia vaccine","volume":"32","author":"Isshiki","year":"2014","journal-title":"Vaccine"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2471\/BLT.19.237149","article-title":"Herpes simplex virus: global infection prevalence and incidence estimates, 2016","volume":"98","author":"James","year":"2020","journal-title":"Bull. World Health Organ."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/gt.2016.3","article-title":"HSV vector-mediated GAD67 suppresses neuropathic pain induced by perineural HIV gp120 in rats through inhibition of ROS and Wnt5a","volume":"23","author":"Kanda","year":"2016","journal-title":"Gene Ther."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.virol.2006.08.007","article-title":"Ability of herpes simplex virus vectors to boost immune responses to dna vectors and to protect against challenge by simian immunodeficiency virus","volume":"357","author":"Kaur","year":"2007","journal-title":"Virology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/00002030-200405210-00019","article-title":"Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector","volume":"18","author":"Kostense","year":"2004","journal-title":"AIDS"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1128\/jvi.74.15.7127-7136.2000","article-title":"Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity","volume":"74","author":"Kruse","year":"2000","journal-title":"J. Virol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1006\/viro.1997.8926","article-title":"Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines","volume":"240","author":"Kuklin","year":"1998","journal-title":"Virology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1472-6750-6-40","article-title":"Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases","volume":"6","author":"Kuroda","year":"2006","journal-title":"BMC Biotechnol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2174\/1570162X17666190618160608","article-title":"Updated studies on the development of HIV therapeutic vaccine","volume":"17","author":"Larijani","year":"2019","journal-title":"Curr. HIV Res."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1099\/vir.0.81104-0","article-title":"Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity","volume":"86","author":"Lauterbach","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1016\/j.vaccine.2016.05.022","article-title":"The combination of Pleurotus ferulae water extract and CpG-ODN enhances the immune responses and antitumor efficacy of HPV peptides pulsed dendritic cell-based vaccine","volume":"34","author":"Li","year":"2016","journal-title":"Vaccine"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1016\/j.vaccine.2009.03.003","article-title":"Genetic engineering of a modified herpes simplex virus 1 vaccine vector","volume":"27","author":"Liu","year":"2009","journal-title":"Vaccine"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/10826068.2015.1045610","article-title":"Expression and immunogenicity of recombinant glycoprotein D of herpes simplex virus 1 in drosophila S2 cells","volume":"46","author":"Mao","year":"2016","journal-title":"Prep. Biochem. Biotechnol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/978-1-4419-1132-2_10","article-title":"HSV as a vector in vaccine development and gene therapy","volume":"655","author":"Marconi","year":"2009","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"100062","DOI":"10.1016\/j.jve.2021.100062","article-title":"Bringing social context into global biomedical HIV cure-related research: an urgent call to action","volume":"8","author":"Miall","year":"2022","journal-title":"J. Virus Erad."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"5958","DOI":"10.1128\/jvi.75.13.5958-5964.2001","article-title":"Immature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1","volume":"75","author":"Mikloska","year":"2001","journal-title":"J. Virol."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"7745","DOI":"10.1128\/jvi.74.17.7745-7754.2000","article-title":"Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus","volume":"74","author":"Murphy","year":"2000","journal-title":"J. Virol."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14760584.2020.1711054","article-title":"The potential of adenoviral vaccine vectors with altered antigen presentation capabilities","volume":"19","author":"Neukirch","year":"2020","journal-title":"Expert Rev. Vaccines"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.vaccine.2016.03.022","article-title":"Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection","volume":"34","author":"Nicoli","year":"2016","journal-title":"Vaccine"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"6764","DOI":"10.1016\/j.vaccine.2007.06.064","article-title":"HIV-1(89.6) gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice","volume":"25","author":"Parker","year":"2007","journal-title":"Vaccine"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e01476-17","DOI":"10.1128\/JVI.01476-17","article-title":"Analysis of select herpes simplex virus 1 (HSV-1) proteins for restriction of human immunodeficiency virus type 1 (HIV-1): HSV-1 gM protein potently restricts HIV-1 by preventing intracellular transport and processing of Env gp160","volume":"92","author":"Polpitiya Arachchige","year":"2018","journal-title":"J. Virol."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1006\/viro.1997.8878","article-title":"Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo","volume":"239","author":"Pushko","year":"1997","journal-title":"Virology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"3930","DOI":"10.1128\/jvi.78.8.3930-3940.2004","article-title":"Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol","volume":"78","author":"Ramsburg","year":"2004","journal-title":"J. Virol."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0092-8674(01)00482-2","article-title":"An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants","volume":"106","author":"Rose","year":"2001","journal-title":"Cells"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.vaccine.2006.11.004","article-title":"Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag","volume":"25","author":"Santos","year":"2007","journal-title":"Vaccine"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1570162033352093","article-title":"HIV vaccine development: lessons from the past and promise for the future","volume":"1","author":"Spearman","year":"2003","journal-title":"Curr. HIV Res."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1099\/0022-1317-76-2-321","article-title":"Replication, establishment of latent infection, expression of the latency-associated transcripts and explant reactivation of herpes simplex virus type 1 \u03b334.5 mutants in a mouse eye model","volume":"76","author":"Spivack","year":"1995","journal-title":"J. Gen. Virol."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0165-2427(02)00227-1","article-title":"FIV vaccine development and its importance to veterinary and human medicine: a review: FIV vaccine 2002 update and review","volume":"90","author":"Uhl","year":"2002","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1089\/104454902760330183","article-title":"Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08","volume":"21","author":"Verrier","year":"2002","journal-title":"DNA Cell Biol."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2144\/01311dd05","article-title":"General strategy for constructing large HSV-1 plasmid vectors that co-express multiple genes","volume":"31","author":"Wang","year":"2001","journal-title":"BioTechniques"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.virol.2006.08.015","article-title":"Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector","volume":"357","author":"Watanabe","year":"2007","journal-title":"Virology"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1172\/JCI116527","article-title":"Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models","volume":"91","author":"Whitley","year":"1993","journal-title":"J. Clin. Invest."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S1072-7515(01)00866-3","article-title":"Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus1","volume":"193","author":"Wong","year":"2001","journal-title":"J. Am. Coll. Surg."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/COH.0b013e32832c0672","article-title":"HIV molecular epidemiology: transmission and adaptation to human populations","volume":"4","author":"Woodman","year":"2009","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"623996","DOI":"10.3389\/fimmu.2021.623996","article-title":"Parainfluenza virus 5 priming followed by SIV\/HIV virus-like-particle boosting induces potent and durable immune responses in nonhuman primates","volume":"12","author":"Xiao","year":"2021","journal-title":"Front. Immunol."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"7662","DOI":"10.1128\/JVI.07164-11","article-title":"HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component","volume":"86","author":"Yang","year":"2012","journal-title":"J. Virol."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e00084-18","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin. Microbiol. Rev."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1136664\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T04:23:05Z","timestamp":1679026985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1136664\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":63,"alternative-id":["10.3389\/fmicb.2023.1136664"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2023.1136664","relation":{},"ISSN":["1664-302X"],"issn-type":[{"type":"electronic","value":"1664-302X"}],"subject":[],"published":{"date-parts":[[2023,3,17]]},"article-number":"1136664"}}